The GABA transporter and its inhibitors

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Gamma-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the central nervous system.
• GABA re-uptake from the synaptic cleft is a key mechanism regulating GABAergic neurotransmission.
• Therapeutic strategies targeting GABAergic systems hold promise for treating epilepsy and psychiatric disorders.

Purpose of the Study:

• To review the structural and mechanistic aspects of GABA transporters.
• To discuss the progress in identifying amino acids involved in substrate binding.
• To explore the structure-activity relationships (SAR) of GABA transporter inhibitors.

Main Methods:

• Literature review of GABA transporter research.
• Analysis of structural and mechanistic data for GABA transporters.
• Examination of SAR studies for GABA transporter inhibitors.

Main Results:

• Currently, only highly selective inhibitors for GABA Transporter 1 (GAT-1) are available, primarily lipophilic derivatives of (R)-nipecotic acid and guvacine.
• NNC-711 and tiagabine are potent inhibitors of human GAT-1, with IC50 values of 0.04 mM and 0.07 mM, respectively.
• Newer analogues, such as a diheteroarylvinyloxy derivative of tiagabine, show even greater potency; however, compounds with significant selectivity for GAT-2, GAT-3, and BGT-1 subtypes remain limited.

Conclusions:

• Selective GAT-1 inhibitors represent a promising therapeutic avenue for neurological and psychiatric conditions.
• Further research is needed to develop subtype-selective inhibitors for GAT-2, GAT-3, and BGT-1 to broaden therapeutic applications.
• Understanding GABA transporter structure and function is crucial for designing effective pharmacological interventions.